Safety of High-Dose Vitamin D Supplementation Among Children Aged 0 to 6 Years

Authors:

Abstract
The influence of vitamin D on skeletal health is well known, but other biological nonskeletal effects have been discovered as the vitamin D receptor has been identified in cell types not involved in bone metabolism.1-3 Vitamin D deficiency is a common global problem,3 particularly in young children,4 and the insight about new biological nonskeletal actions of vitamin D demands revision of vitamin D supplementation policies,1 which have led to updated recommendations regarding clinical practice and recommended intake levels. Vitamin D is primarily obtained by cutaneous synthesis from sunlight exposure or as a nutrient from dietary sources such as fatty fish.5 However, as treatment and in prevention of deficiency, vitamin D supplements in the form of either cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2) have been recommended.6 Supplementation of very high doses of vitamin D can cause hypercalcemia and subsequent kidney failure; therefore, an upper threshold concentration of serum 25-hydroxyvitamin D (25[OH]D) corresponding to 100 ng/mL (to convert to nanomoles per liter, multiply by 2.496) has been suggested by the Endocrine Society, at which the risk of developing hypercalcemia is considered minimal.6 Regarding intake, a tolerable upper intake level has been defined as 25 μg/d (1000 IU/d) for infants aged 0 to 12 months and 50 μg/d (2000 IU/d) for children aged 1 to 10 years by the European Food Safety Authority.3 In general, evidence from systematic reviews and meta-analyses evaluating the safety of high-dose vitamin D supplementation in early childhood is lacking. Therefore, the purpose of this study was to investigate the safety of high-dose vitamin D in children aged 0 to 6 years by examining potential clinical adverse events and biochemical changes reported in randomized clinical trials (RCTs).

This publication has 42 references indexed in Scilit: